Evidence map›Paper›PMID 27903237›Full record

ArticleBMC neuroscience2016

Leucine-rich repeat kinase 2 (LRRK2) regulates α-synuclein clearance in microglia.

Tatsunori Maekawa, Toshikuni Sasaoka, Sadahiro Azuma, Takafumi Ichikawa, Heather L Melrose, Matthew J Farrer, Fumiya Obata

Open access · goldAbstract read
In one paragraph

Article in BMC neuroscience, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
34citing papers in PubMed, 1 pooled it
3.8field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

34 citing papers in PubMed, 1 synthesis or guideline pooled it, 62 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Exploring LRRK2-dependent Mechanisms in Parkinson's Disease Therapy.CNS & neurological disorders drug targets · 2025
    Review
  5. Review
  6. Article
  7. Review
  8. Article
  9. Review
  10. Article
  11. Review
  12. Article
  13. Review
  14. Exploring the focal role of LRRK2 kinase in Parkinson's disease.Environmental science and pollution research international · 2022
    Review
  15. Article
  16. Review
  17. Neurons and Glia Interplay in α-Synucleinopathies.International journal of molecular sciences · 2021
    Review
  18. Review
  19. Frontiers in cellular neuroscience · 2021
    Review
  20. Genetic and Environmental Factors in Parkinson's Disease Converge on Immune Function and Inflammation.Movement disorders : official journal of the Movement Disorder Society · 2021
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 4 institutions in 3 countries.

Tatsunori MaekawaDepartment of Biochemistry, Graduate School of Medical Sciences, Kitasato University, 1-15-1 Kitasato, Minami-ku, Sagamihara, Kanagawa, 252-0373, Japan. maekawa@kitasato-u.ac.jp.ORCID 0000-0002-1214-9959
Toshikuni SasaokaDepartment of Laboratory Animal Science, Kitasato University School of Medicine, 1-15-1 Kitasato, Minami-ku, Sagamihara, Kanagawa, 252-0373, Japan.
Sadahiro AzumaDepartment of Laboratory Animal Science, Kitasato University School of Medicine, 1-15-1 Kitasato, Minami-ku, Sagamihara, Kanagawa, 252-0373, Japan.
Takafumi IchikawaDepartment of Biochemistry, Graduate School of Medical Sciences, Kitasato University, 1-15-1 Kitasato, Minami-ku, Sagamihara, Kanagawa, 252-0373, Japan.
Heather L MelroseDepartment of Neuroscience, Mayo Clinic, 4500 San Pablo Rd S, Jacksonville, FL, 32224, USA.
Matthew J FarrerDepartment of Medical Genetics, Centre for Applied Neurogenetics, Djavad Mowafaghian Centre for Brain Health, University of British Columbia, 2329 West Mall, Vancouver, BC, V6T 1Z4, Canada.
Fumiya ObataDivision of Clinical Immunology, Graduate School of Medical Sciences, Kitasato University, 1-15-1 Kitasato, Minami-ku, Sagamihara, Kanagawa, 252-0373, Japan.
Kitasato University · JPMayo Clinic in Florida · USNational Institute for Basic Biology · JPUniversity of British Columbia · CA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundα-Synuclein (αSYN) has been genetically implicated in familial and sporadic Parkinson's disease (PD), and is associated with disease susceptibility, progression and pathology. Excess amounts of αSYN are toxic to neurons. In the brain, microglial αSYN clearance is closely related to neuronal survival. Leucine-rich repeat kinase 2 (LRRK2) is the one of the other genes implicated in familial and sporadic PD. While LRRK2 is known to be expressed in microglia, its true function remains to be elucidated. In this study, we investigated αSYN clearance by microglia isolated from LRRK2-knockout (KO) mice.

resultsIn LRRK2-KO microglia, αSYN was taken up in larger amounts and cleared from the supernatant more effectively than for microglia isolated from wild-type (WT) mice. This higher clearance ability of LRRK2-KO microglia was thought to be due to an increase of Rab5-positive endosomes, but not Rab7- or Rab11-positive endosomes. Increased engagement between Rab5 and dynamin 1 was also observed in LRRK2-KO microglia.

conclusionLRRK2 negatively regulates the clearance of αSYN accompanied by down-regulation of the endocytosis pathway. Our findings reveal a new functional role of LRRK2 in microglia and offer a new insight into the mechanism of PD pathogenesis.

Indexed as

alpha-SynucleinAnimalsBlotting, WesternBrainCells, CulturedDynamin IEndocytosisEndosomesFluorescent Antibody TechniqueLeucine-Rich Repeat Serine-Threonine Protein Kinase-2Mice, Inbred C57BLMice, KnockoutMicrogliarab5 GTP-Binding ProteinsRecombinant Proteinsalpha-SynucleinDynamin ILeucine-Rich Repeat Serine-Threonine Protein Kinase-2Lrrk2 protein, mouserab5 GTP-Binding ProteinsRecombinant ProteinsSnca protein, mouseLRRK2Microgliaα-Synuclein

Identifiers

PMID27903237
PMCPMC5131420
OpenAlexW2559466447

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.